Quantum BioPharma announces through its subsidiary, Huge Biopharma Australia, the submission of its patented candidate breakthrough drug, Lucid-21-302, to the Innovative Licensing and Access Pathway Passport program in the United Kingdom. The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Announces Private Placement to Bolster Financial Position
- Quantum BioPharma’s Unbuzzd Wellness Launches $5 Million Capital Raise
- Quantum licensee Unbuzzd Wellness launches $5M Reg D capital raise
- Quantum BioPharma and MGH Launch MS Study with Novel Imaging Technique
- Quantum Group announces first person with MS scanned in joint study